Cost-Effectiveness of Prophylactic Medications for the Treatment of Hereditary Angioedema Due to C1 Inhibitor Deficiency: A Real-World U.S. Perspective.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30698094.
- Also identified by DOI 10.18553/jmcp.2019.25.2.148 and PMC identifier 10398223.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No funding supported the writing of this commentary. The author reports personal fees from BioCryst, CSL Behring, Shire, and Pharming and grants from Ionis. He is chair of the US HAEA Medical Advisory Board and scientific advisor for HAE International.
Medical subject headings
- Hereditary Angioedema Types I and II
- Models, Economic